Fecal Microbiota Transplantation in Parkinson's Disease.
ConditionParkinson's Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChang Gung Memorial Hospital
About this trial
Fecal microbiota transplantation (FMT) is an effective and safe treatment for Clostridioides difficile infection (CDI). Though CDI is the only indication for FMT, more and more preliminary data on FMT in neurological disorders are reported due to gut-brain axis. This study is a pilot study to apply FMT on patients with Parkinson's disease (PD). The effect of FMT on motor and non-motor symptoms in PD will be also evaluated.
Eligibility criteria
Qualifiers
Clinical diagnosis of idiopathic PD according to UK brain bank criteria.
PD disease duration ≧5 years to avoid the possible misdiagnosis of atypical parkinsonism.
Hoehn-Yahr stage 1-4
Using levodopa in a currently fixed dose.
Disqualifiers
Hoehn-Yahr stage 5. (wheelchair ridden or bedridden due to PD)
Dementia (MMSE<24), history of encephalitis, or brain organic lesions, including congenital or acquired structural abnormalities (which were detected through brain computed tomography scan or Magnetic Resonance Imaging) may affect neurological function, leading to various neurological deficits and mpairing the cognitive function.
Current use of probiotics or in the past 3 months.
For women with childbearing potential. (Female participants are suggested to prevent pregnancy during this trial and undergo a pregnancy test before enrollment.)
Trial design
Treatments tested in this trial
- Fecal microbiota transplantation
- Not received Fecal microbiota transplantation
Treatment groups
58 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov